scholarly article | Q13442814 |
P2093 | author name string | Madeleine Duvic | |
Steven T Rosen | |||
Joan Guitart | |||
Youn H Kim | |||
Stephen W Dusza | |||
Christiane Querfeld | |||
Timothy M Kuzel | |||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | phase II clinical trial | Q42824440 |
mycosis fungoides | Q1891209 | ||
multicenter clinical trial | Q6934595 | ||
P304 | page(s) | 1159-1166 | |
P577 | publication date | 2013-12-11 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome | |
P478 | volume | 123 |
Q48296904 | Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. |
Q34516083 | Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents |
Q36470196 | Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management |
Q48034709 | Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. |
Q90070199 | Cutaneous lymphomas : Clinical presentation - diagnosis - treatment |
Q49356636 | Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy. |
Q98165138 | Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab |
Q42087653 | Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities |
Q33430525 | Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study |
Q64235061 | Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma |
Q90102093 | Mycosis fungoides: Developments in incidence, treatment, and survival |
Q55334211 | New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. |
Q64883379 | Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. |
Q26774768 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas |
Q26772207 | Primary cutaneous lymphomas: diagnosis and treatment |
Q52962544 | Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide. |
Q90485191 | Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases |
Q88153215 | Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome |
Q38229634 | Targeted therapies for cutaneous T-cell lymphomas |
Q41573605 | The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines |
Q35071772 | c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death |